Song Zhengbo, Yu Xinmin, Zhang Yiping
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Clinics (Sao Paulo). 2015 Dec;70(12):775-80. doi: 10.6061/clinics/2015(12)03.
The role of chemotherapy in treating advanced thymic carcinoma is unclear. The purpose of the current study was to investigate the efficacy of chemotherapy and the prognostic factors for patients with advanced thymic carcinoma.
A retrospective review of the medical records of 86 patients treated with chemotherapy for advanced thymic carcinoma was conducted between 2000 and 2012 at our institution. The clinical characteristics, chemotherapy regimens and prognostic factors were analyzed. Survival curves were plotted using the Kaplan-Meier method and the Cox proportional hazard model was used for multivariate analysis.
Of the 86 patients, 56 were male and 30 were female. The median survival time was 24.5 months. For the first-line chemotherapy treatment, the objective response rate was 47.7% and the disease control rate was 80.2%. The median progression-free survival for all patients was 6.5 months for first-line chemotherapy. No significant differences in progression-free survival were observed among the different chemotherapy regimens. Multivariate analyses revealed that the prognostic factors for overall survival included performance status (p=0.043), histology grade (p=0.048), and liver metastasis (p=0.047).
Our results suggest that there is no difference in efficacy between multiagent and doublet regimens. The prognosis of patients with advanced thymic carcinoma can be predicted based on histological grade, liver metastasis and performance status.
化疗在晚期胸腺癌治疗中的作用尚不清楚。本研究旨在探讨晚期胸腺癌患者化疗的疗效及预后因素。
对2000年至2012年在我院接受化疗的86例晚期胸腺癌患者的病历进行回顾性分析。分析临床特征、化疗方案及预后因素。采用Kaplan-Meier法绘制生存曲线，并使用Cox比例风险模型进行多因素分析。
86例患者中，男性56例，女性30例。中位生存时间为24.5个月。一线化疗的客观缓解率为47.7%，疾病控制率为80.2%。所有患者一线化疗的中位无进展生存期为6.5个月。不同化疗方案之间的无进展生存期无显著差异。多因素分析显示，总生存的预后因素包括体能状态（p=0.043）、组织学分级（p=0.048）和肝转移（p=0.047）。
我们的结果表明，多药联合方案与双药方案的疗效无差异。晚期胸腺癌患者的预后可根据组织学分级、肝转移和体能状态进行预测。
